The burgeoning sector is primarily focused on human health, with 39.7% of enterprises utilizing biotechnology for developing therapeutics, diagnostics, and drug delivery technologies. Non-GM agricultural biotechnology and non-specific biotechnology applications account for 29.7% and 24.3% of activities, respectively.
A key driver of growth is the increasing number of enterprises with biotechnology products on the market. In 2023, 400 enterprises had products available, up from 302 in 2020. Additionally, 130 enterprises hold approved biotechnology patents, demonstrating a strong commitment to innovation and intellectual property.
The sector's rapid expansion is fueled by significant investments in research and development. In 2023, biotechnology R&D expenditure reached 2.493 billion Turkish Lira, a substantial increase from 446 million Lira in 2020.
To support this growth, the sector relies on a skilled workforce of 3,987 individuals, with a significant proportion holding advanced degrees. However, challenges such as access to capital, skilled human resources, and international markets remain significant obstacles.
Despite these challenges, Türkiye's biotechnology sector is poised for further growth, driven by government support, increasing global demand, and the potential to address critical health and agricultural challenges. (ILKHA)